Ben Stevens
Ben is the editor of Business of Cannabis. Since 2021, he has researched, written, and published the vast majority of the outlet’s content, delivering agenda-setting journalism on regulation, business strategy, and policy across Europe.
Ben Stevens · page 48
- Medical
Poland’s MedCan Crackdown Sees Bump in Sales, Ireland’s Cannabis Future Uncertain Post-Election, & Maltese Associations Raise Concerns Over Regulator Changes
Poland Last month Poland’s Ministry of Health enacted new legislation preventing medical cannabis patients from securing prescriptions online.
- Uncategorized
Hunter Biden Pardon Sparks Intensified Calls for Federal Cannabis Clemency, With Suggestions More Could Be On the Way
Joe Biden’s controversial pardon of his son Hunter Biden has seen pressure build on the outgoing US president to make good on his promises of widespread clemency for low-level cannabis convictions.
- Uncategorized
Colorados Falling Sales Drives Boom in Lower Strength Cannabis Products
The continued decline of cannabis sales in Colorado is seeing a boom in lower THC cannabis products.
- Uncategorized
Legal Fight to Overturn Federal Cannabis Ban Faces Uphill Battle in Appeals Court
Ongoing legal efforts to overturn the federal prohibition of cannabis were heard in the US Court of Appeals this week yesterday, but plaintiffs seemingly failed to convince the judges of their arguments.
- Uncategorized
Cannabis Rescheduling Hearing Set to Begin on January 21 for 6 Weeks, As Frustrations Over Process Continue to Build
The Drug Enforcement Administration (DEA) has scheduled an official date for the highly anticipated public hearing on cannabis rescheduling, starting with a presentation from the government just a day after President Elect Donald Trump is sworn in.
- Events
Shaping Germany’s Cannabis Future: Insights from the Berlin Executive Summit
Last week, the Business of Cannabis: Berlin Executive Summit welcomed over 150 executives, policymakers, and thought leaders to take stock of how the first eight months of Germany’s landmark CanG bill had impacted the market and discuss how the uncertain future could play out.
- Markets & Stocks
First Cannabis Company in History to List on LSE Announces Intention to Leave, Ananda Reaches New Research Milestone & More From Denmark
Argent Biopharma [stock_market_widget type=”chart” template=”line” assets=”RGT.L” range=”1mo” interval=”1d” price_field=”close” border_width=”3″ tension=”0.5″ line_color=”#5679FF” range_selector=”true” axes=”true” cursor=”true” api=”yahoo-finance”] Argent Biopharma (previously MGC Pharmaceuticals), the first company in history to launch an IPO on the London Stock Exchange, has announced its intention to de-list from the exchange.
- Adult-Use
US Cannabis Sales to Hit $32bn This Year as Industry Continues Record Growth
The US cannabis industry is experiencing rapid growth, with retail sales projected to exceed $32bn in 2024 and wholesale sales reaching nearly $12bn, according to a new study from Leaflink.
- CBD Market
UK CBD Industry Sees Light at the End of the Tunnel: First Authorised Products Expected by Spring 2025
In a long-awaited and major step forward for the UK’s CBD sector, the regulator has announced a new roadmap that could see the first products given official approval by Spring next year.
- Medical
Compliance Meets Compassion: How Releaf’s Training Standards Set the Benchmark for Medical Cannabis in the UK
The medical cannabis sector in the UK is navigating a dual imperative: ensuring rigorous compliance with regulatory standards while delivering compassionate care to patients in need. For UK medical cannabis clinic Releaf, these two objectives are not only complementary but also foundational to its operations.
- Uncategorized
DEA Cannabis Rescheduling Hearing Takes Landmark First Step
The first step in the US’s landmark efforts to reschedule cannabis officially took place yesterday, setting the stage for what is set to be a lively and heated process.
- Press releases
Cannavigia to Expand US Operations as Medical Cannabis Rescheduling Remains a Focus
CANNAVIGIA (by Vigia AG), a global pioneer in cannabis compliance software and consulting, is expanding its presence in the U.S. market, building on recent regulatory developments related to the potential rescheduling of medical cannabis to Schedule III.












